BIO 2025 brings pharma, biotech, and policy leaders together to tackle industry challenges. Follow our coverage on AI, vaccines, cell & gene therapy, and key discussions from health officials.

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and ...

BARDA has given $24 million to Locus Bio to support a mid-stage trial of bacteriophage therapy LBP-EC01 for resistant E coli infections.

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS ...

Bayer has stepped up the digital capabilities of its radiology business with the launch of artificial intelligence-based apps for X-ray, MRI and CT imaging. The cloud-hosted platform – called ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at up to ...

New Zealand medical tech startup Alimetry has claimed an FDA approval for a wearable device that can be used to diagnose gastric disorders non-invasively. The Gastric Alimetry device will be ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 ...

Executing an effective commercial success strategy requires extensive planning and implementation within pharmaceutical companies that spans teams, functions, and geographies. Together, these ...

La Jolla Pharmaceuticals' dreams of building a lucrative business from its stable of drugs used in infectious diseases never really paid off, and the company has now sold itself to royalty and ...

Sanofi reached civil settlement with the US SEC and agreed to pay multi-million dollars settlement resolving yearslong bribery investigation.